Our Mission: make pancreatic cancer, the 2nd leading cause of cancer death by 2020, a treatable condition by applying next-gen liquid biopsy diagnostics.

The Problem

Pancreatic Cancer is one of the most lethal cancers due to over 90% of cases being diagnosed at an advanced, incurable stage

While overall 5-year survival of metastatic pancreatic cancer is <5%, outcomes dramatically improve when it is detected early.  

Our Solution

Since development of metastatic pancreatic cancer from its precursor lesions may take up to 20 years, there is a large window of opportunity for earlier detection.  

Using our Next-gen Biomarker DiscoveryPlatform, combined with Innovative 'Big Data' Omics, BiomaRx is developing a multi-analyte liquid biopsy.

This carries the potential to be the first ever non-invasive biomarker set to accurately detect pancreatic cancer before it becomes invasive and distinguish between patients with and without advanced pancreatic cancer.

Our diagnostic test will shift the detection of pancreatic cancer to an earlier stage when therapeutic intervention is a viable option.

Developed at Harvard Medical School, biomaRx has applied a disruptive, proprietary systems biology engine to identify and deliver first-in-class therapeutics for high priority drug targets in pancreatic cancer.

About BiomaRx

Based out of Cambridge, MA, BiomaRx is a seed-stage venture focused on making pancreatic cancer a treatable condition through early diagnosis. The team is developing a non-invasive diagnostic for pancreatic cancer, a disease that is projected to be the second leading cancer killer by 2020.

Spun out of Harvard Medical School and Beth Israel Deaconess Medical Center, BiomaRx uses a proprietary systems biology engine to identify next-gen diagnostic biomarkers and therapeutic targets for first-in class pancreatic cancer diagnosis and treatment.